ERNA — Eterna Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$4.35
-$0.22 (-4.81%)
Eterna Therapeutics Inc (ERNA) is a biotechnology company listed on NASDAQ. It is led by Sanjeev Luther, based in 1035 Cambridge Street, Cambridge, MA, United States, 02141, with about 5 employees. Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Net income was -$1.2M. ERNA currently screens at market cap $6.9M and trailing P/E 0.0.
Use this ERNA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ERNA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ERNA SEC filings page. Lician reads the product cache first so this HTML stays unique to Eterna Therapeutics Inc even when a live quote feed is slow.
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
ERNA Key Statistics
Market Cap
$6.87M
Volume
49,565
Previous Close
$5.04
Day Range
$4.92 – $5.51
P/E Ratio
0.00
P/B Ratio
1.00
EPS
-$3.26
Revenue
$582.00K
Net Income
-$44.54M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+755.9%
Profit Margin
-7652.7%
Employees
5
ERNA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $582.00K | $68.00K | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$44.54M | -$21.67M | -$24.58M | -$122.55M |
| EPS (Diluted) | -$3.26 | -$4.08 | -$8.06 | -$56.61 |
Total Assets
$5.27M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.73M
Operating Cash Flow
-$15.84M
Free Cash Flow
$0.00
Eterna Therapeutics Inc Company Information
- CEO, President & Director
- Sanjeev Luther
- Headquarters
- 1035 Cambridge Street, Cambridge, MA, United States, 02141
- Website
- www.ernexatx.com
- Phone
- 617 798 6700
- IPO / Founded
- 1992-10-19
- Sector
- Healthcare
- Industry
- Biotechnology